Ignite Creation Date:
2025-12-25 @ 12:44 AM
Ignite Modification Date:
2026-02-02 @ 1:30 AM
Study NCT ID:
NCT00057967
Status:
COMPLETED
Last Update Posted:
2019-02-06
First Post:
2003-04-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
Sponsor:
Northwestern University
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Lymphoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | recurrent mycosis fungoides/Sezary syndrome | View |
| None | stage I mycosis fungoides/Sezary syndrome | View |
| None | stage II mycosis fungoides/Sezary syndrome | View |
| None | stage III mycosis fungoides/Sezary syndrome | View |
| None | stage IV mycosis fungoides/Sezary syndrome | View |
| None | recurrent cutaneous T-cell non-Hodgkin lymphoma | View |
| None | stage I cutaneous T-cell non-Hodgkin lymphoma | View |
| None | stage II cutaneous T-cell non-Hodgkin lymphoma | View |
| None | stage III cutaneous T-cell non-Hodgkin lymphoma | View |
| None | stage IV cutaneous T-cell non-Hodgkin lymphoma | View |